Nikkei 225 Edges Higher as Pharma Leads, SoftBank Tumbles 7%
The Nikkei 225 closed marginally higher at ¥38,308, gaining 0.12% in a mixed session that saw pharmaceutical stocks lead gains while SoftBank Group suffered a dramatic 6.95% decline on Monday.
Yen Weakness Provides Modest Support for Exporters
The USD/JPY pair held near recent highs at ¥163.68, with the weak yen continuing to provide tailwinds for Japan’s export-heavy market. This currency backdrop helped lift several major exporters, including Sony Group (+1.40%) and Nintendo (+1.43%), as investors positioned for stronger overseas earnings translations.
The yen’s persistent weakness against the dollar has become a defining theme for Japanese equities this year, with many multinational corporations benefiting from the favorable exchange rate environment when converting foreign revenues back to yen.
Takeda Leads Healthcare Rally Amid Global Risk-Off Sentiment
Takeda Pharmaceutical emerged as the session’s standout performer, surging 2.50% to ¥2,723.92 as investors rotated into defensive healthcare names. The pharmaceutical giant’s strong performance came against a backdrop of geopolitical tensions, with reports of a pause in US-Iran fighting providing some relief to global markets after weekend escalations.
The broader risk-off sentiment was evident in commodity markets, where oil prices slipped 4% following the temporary de-escalation. This environment typically favors defensive sectors like pharmaceuticals and utilities, explaining the strong performance across healthcare names.
SoftBank Suffers Sharp Decline as Tech Sentiment Sours
SoftBank Group dominated the losers’ board with a steep 6.95% drop to ¥2,580.14, reflecting broader concerns about the technology investment conglomerate’s portfolio exposure amid uncertain global conditions. The decline came as investors reassessed risk appetite following weekend geopolitical developments and ahead of key Federal Reserve policy decisions.
Industrial automation specialist Fanuc also faced selling pressure, falling 3.05% to ¥3,163.16, suggesting investor caution around cyclical technology plays. The divergence between defensive healthcare stocks and growth-oriented technology names highlighted the market’s current risk-averse positioning.
BOJ Policy Outlook Remains in Focus
With the next Bank of Japan meeting scheduled for April 28, 2026, market participants continue to monitor Governor Ueda’s policy stance amid ongoing US-China trade tensions. Current expectations point to a hold at the current rate, with investors particularly focused on any hawkish surprises that could strengthen the yen and impact exporter competitiveness.
Monday’s modest gains reflected the market’s cautious optimism as investors balanced geopolitical risks against supportive currency conditions. The session’s mixed performance, with defensive sectors outpacing growth names, suggests market participants remain selective in their positioning as they navigate an increasingly complex global landscape. For NISA investors, the current environment may favor diversified approaches that capture both the yen’s weakness through exporters and defensive positioning through healthcare and financial names.
This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results. Please consult with a qualified financial advisor before making investment decisions.